NZ506153A - Method of inhibiting membrane-type matrix metalloproteinase using tetracycline compounds - Google Patents

Method of inhibiting membrane-type matrix metalloproteinase using tetracycline compounds

Info

Publication number
NZ506153A
NZ506153A NZ506153A NZ50615399A NZ506153A NZ 506153 A NZ506153 A NZ 506153A NZ 506153 A NZ506153 A NZ 506153A NZ 50615399 A NZ50615399 A NZ 50615399A NZ 506153 A NZ506153 A NZ 506153A
Authority
NZ
New Zealand
Prior art keywords
cmt
tetracycline
mmp
dimethylamino
activity
Prior art date
Application number
NZ506153A
Other languages
English (en)
Inventor
Lorne M Golub
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of NZ506153A publication Critical patent/NZ506153A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ506153A 1998-03-31 1999-03-30 Method of inhibiting membrane-type matrix metalloproteinase using tetracycline compounds NZ506153A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/052,222 US6277061B1 (en) 1998-03-31 1998-03-31 Method of inhibiting membrane-type matrix metalloproteinase
PCT/US1999/006972 WO1999049871A1 (en) 1998-03-31 1999-03-30 Method of inhibiting membrane-type matrix metalloproteinase

Publications (1)

Publication Number Publication Date
NZ506153A true NZ506153A (en) 2003-10-31

Family

ID=21976191

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ506153A NZ506153A (en) 1998-03-31 1999-03-30 Method of inhibiting membrane-type matrix metalloproteinase using tetracycline compounds

Country Status (8)

Country Link
US (2) US6277061B1 (enExample)
EP (1) EP1079837A4 (enExample)
JP (1) JP2002509889A (enExample)
KR (1) KR20010042322A (enExample)
AU (1) AU748870B2 (enExample)
CA (1) CA2320260A1 (enExample)
NZ (1) NZ506153A (enExample)
WO (1) WO1999049871A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506740B1 (en) * 1998-11-18 2003-01-14 Robert A. Ashley 4-dedimethylaminotetracycline derivatives
EP1174129A1 (en) * 2000-07-17 2002-01-23 Zenner, Hans Peter, Prof. Dr. med. Use of a matrix-metalloprotease inhibitor for the treatment of cancer
EP2329826A1 (en) 2001-07-13 2011-06-08 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of multiple sclerosis
CA2462572C (en) * 2001-10-05 2008-11-18 Tetragenex Pharmaceuticals, Inc. Tetracycline derivatives and methods of use thereof
IL162213A0 (en) * 2001-12-03 2005-11-20 Novacea Inc Pharmaceutical compositions containing active vitamin d compounds
WO2003053447A1 (en) * 2001-12-20 2003-07-03 Hanauske-Abel Hartmut M Treatment for averting or delaying premature delivery
EP2322501B1 (en) 2002-01-08 2015-08-05 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
KR101014918B1 (ko) 2002-03-08 2011-02-15 파라테크 파마슈티컬스, 인크. 아미노-메틸 치환된 테트라시클린 화합물
EP2481723A3 (en) 2002-03-21 2013-02-13 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
EP2250887B1 (en) * 2002-03-29 2013-04-24 The Research Foundation Of The State University Of New York Use of non-antibacterial tetracycline analog CMT-1002 and formulations thereof for the treatment of bacterial exotoxins
EP2345637A3 (en) 2002-07-12 2012-02-15 Paratek Pharmaceuticals, Inc. 3, 10, and 12a substituted tetracycline compounds
US20040170621A1 (en) * 2002-08-30 2004-09-02 Roodman G. David Method of resisting osteoclast formation
US20040138162A1 (en) * 2002-08-30 2004-07-15 Roodman G. David Method of resisting osteoclast formation
EP1562608A4 (en) 2002-10-24 2010-09-01 Paratek Pharm Innc METHOD OF USE OF SUBSTITUTED TETRACYCLINE COMPOUNDS FOR MODULATING THE RNA
CA2511521C (en) 2002-12-30 2012-02-07 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CA2531728A1 (en) 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
JP4738333B2 (ja) 2003-07-09 2011-08-03 パラテック ファーマシューティカルズ インコーポレイテッド ９−アミノメチルテトラサイクリン化合物のプロドラッグ
WO2005070878A1 (en) * 2004-01-15 2005-08-04 Paratek Pharmaceuticals, Inc. Aromatic a-ring derivatives of tetracycline compounds
EP1805134B1 (en) 2004-10-25 2012-06-20 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
EP2269978A3 (en) 2004-10-25 2011-09-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
WO2007014154A2 (en) * 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
US20070142337A1 (en) * 2005-12-15 2007-06-21 The Regents Of The University Of California Treatment of inflammation and organ dysfunction
IL302749A (en) 2006-12-21 2023-07-01 Paratek Pharm Innc A tetracycline compound, a pharmaceutical preparation containing the tetracycline compound, and the tetracycline compound or the pharmaceutical preparation for the treatment of the tetracycline-responsive condition
TR201818983T4 (tr) * 2006-12-21 2019-01-21 Paratek Pharm Innc İnflamatuvar Cilt Bozukluklarının Tedavisine Yönelik Olarak Sübstitüe Edilmiş Tetrasiklin Bileşikleri
EP2213655A1 (en) 2007-04-27 2010-08-04 Paratek Pharmaceuticals, Inc. Methods For Purifying Aminoalkyl Tetracycline Compounds
CN101811980A (zh) * 2007-07-06 2010-08-25 帕拉特克药品公司 合成取代的四环素化合物的方法
TW202216656A (zh) 2008-05-19 2022-05-01 美商Ｐｒｔｋ Ｓｐｖ２公司 四環素化合物之甲苯磺酸鹽及同素異形體
CN105367440A (zh) 2008-08-08 2016-03-02 四相制药公司 C7-氟取代的四环素化合物
CN102459153A (zh) 2009-05-08 2012-05-16 四相制药公司 四环素类化合物
PL2470500T3 (pl) 2009-08-28 2018-03-30 Tetraphase Pharmaceuticals, Inc. Związki tetracyklinowe
JP5820462B2 (ja) 2010-03-31 2015-11-24 テトラフェース ファーマシューティカルズ，インコーポレイテッド 多環式テトラサイクリン化合物
HRP20191295T8 (hr) 2011-05-12 2020-02-07 Paratek Pharmaceuticals, Inc. Kristalne soli amida (4s,4as,5ar,12as)-4-dimetilamino-3,10,12,12a-tetrahidroksi-7-[(metoksi(metil)amino)-metil]-1,11-diokso-1,4,4a,5,5a,6,11,12a-oktahidro-naftacen-2-karboksilne kiseline i postupci uporabe istih
SMT201900096T1 (it) 2012-08-31 2019-02-28 Tetraphase Pharmaceuticals Inc Composti di tetracicline
JP7492335B2 (ja) 2016-10-19 2024-05-29 テトラフェース ファーマシューティカルズ，インコーポレイテッド エラバサイクリンの結晶形
WO2020097450A1 (en) 2018-11-09 2020-05-14 Tetraphase Pharmaceuticals, Inc. Polymorphic forms of a compound and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704383A (en) * 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4925833A (en) * 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
WO1992012717A2 (en) 1991-01-15 1992-08-06 A composition containing a tetracycline and use for inhibiting angiogenesis
DE69304292T2 (de) * 1992-11-17 1997-01-02 Univ New York Tetracycline inclusive nicht antimicrobiel wirksame, chemisch modifizierte Tetracycline hemmende exzessive Kollagenquervernetzung bei Diabetes
US5668122A (en) * 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
GB9615976D0 (en) 1996-07-30 1996-09-11 Center For Clinical & Basic Re The use of proteinase inhibitors for the prevention or reduction of bone resorption
US5789395A (en) * 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth

Also Published As

Publication number Publication date
AU3457699A (en) 1999-10-18
WO1999049871A8 (en) 1999-12-02
EP1079837A4 (en) 2003-07-02
US20020045603A1 (en) 2002-04-18
EP1079837A1 (en) 2001-03-07
US6277061B1 (en) 2001-08-21
CA2320260A1 (en) 1999-10-07
JP2002509889A (ja) 2002-04-02
WO1999049871A1 (en) 1999-10-07
KR20010042322A (ko) 2001-05-25
AU748870B2 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
AU748870B2 (en) Method of inhibiting membrane-type matrix metalloproteinase
AU729886B2 (en) Method of inhibiting cancer growth
ES2237945T3 (es) Combinacion de bisfosfonato y tetraciclina.
ES2241124T3 (es) Actividad inhibidora de serin-proteinasa mediante tetraciclina hidrofoba.
Vartak et al. Matrix metalloproteases: underutilized targets for drug delivery
JP2676080B2 (ja) 非抗バクテリア性テトラサイクリン組成物
Davies et al. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts
ES2578618T3 (es) Composiciones que comprenden proteasa, amilasa y lipasa para su uso en el tratamiento de infecciones por Staphylococcus aureus
EP0671942B1 (en) Pharmaceutical preparation comprising a beta-lactam antibiotic degrading compound, and use thereof
US20090269405A1 (en) Enzyme mediated delivery system
WO2001034176A1 (en) A method and composition for treating prostate cancer
EP1459738A1 (en) Pharmaceutical composition having thrombolytic, anti-inflammatory and cytoprotective properties
US6429204B1 (en) Method of inhibiting cancer growth
US20070027064A1 (en) Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for the use thereof
CZ127295A3 (en) Pharmaceutical preparation exhibiting modulation effect on malignant tumors and the use thereof
JP4630661B2 (ja) 線維症および瘢痕形成の治療におけるコンバターゼインヒビターの使用
Rathna et al. Recent Insights of Matrix Metalloproteinase Inhibitors in Therapeutic Applications
Frimodt-Möller et al. Co-trimazine distribution in the canine prostate
MXPA99006554A (en) Method of inhibiting cancer growth
Cawston Mechanisms of Joint Destruction and Therapeutic Approaches

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)